Association of β2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD

Respirology

Volumn 13, Issue 3, 2008, Pages 346-352

  Umeda, Nobuaki ^a   Yoshikawa, Takahiro ^a,b   Kanazawa, Hiroshi ^a   Hirata, Kazuto ^a   Fujimoto, Shigeo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b School of Medicine   (Japan)

Author keywords

2 adrenoreceptor polymorphism; COPD; G protein coupled receptors; Health related quality of life; Muscarinic acetylcholine receptor antagonist

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; GENOMIC DNA; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; SALBUTAMOL; SCOPOLAMINE DERIVATIVE; TIOTROPIUM;

ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SPIROMETRY; TREATMENT DURATION; ALLELE; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESISTANCE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HOSPITALIZATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; ALBUTEROL; ALLELES; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX;

EID: 41849132820     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2008.01259.x     Document Type: Article

References (30)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997 349 : 1269 76.
2. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004 364 : 709 21.
3. Barnes PJ. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999 160 : S72 9.
4. National Heart, Lung, and Blood Institute. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2006 update). Bethesda, MD : National Institutes of Health. [Accessed 23 April 2007.] Available from GOLD website: http://www.goldcopd.com
5. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N. Engl. J. Med. 1984 311 : 421 5.
6. Caulfield MP, Birdsall NJ. International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 1998 50 : 279 90.
7. Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci. 1993 52 : 521 7.
8. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005 2 : 297 304.
9. Han SJ, Hamdan FF, Kim SK, Jacobson KA, Bloodworth LM et al. Identification of an agonist-induced conformational change occurring adjacent to the ligand-binding pocket of the M3 muscarinic acetylcholine receptor. J. Biol. Chem. 2005 280 : 34849 58.
10. Nahorski SR, Tobin AB, Willars GB. Muscarinic M3 receptor coupling and regulation. Life Sci. 1997 60 : 1039 45.
11. Proskocil BJ, Fryer AD. Beta2-agonist and anticholinergic drugs in the treatment of lung disease. Proc. Am. Thorac. Soc. 2005 2 : 305 10.
12. Zaagsma J, Roffel AF, Meurs H. Muscarinic control of airway function. Life Sci. 1997 60 : 1061 8.
13. Liu M, Simon MI. Regulation by cAMP-dependent protein kinase of a G-protein-mediated phospholipase C. Nature 1996 382 : 83 7.
14. Budd DC, Challiss RA, Young KW, Tobin AB. Cross talk between m3-muscarinic and beta 2-adrenergic receptors at the level of receptor phosphorylation and desensitization. Mol. Pharmacol. 1999 56 : 813 23.
15. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R et al. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004 364 : 1505 12.
16. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am. Rev. Respir. Dis. 1992 145 : 1321 7.
17. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 1997 100 : 3184 8.
18. Weir TD, Mallek N, Sandford AJ, Bai TR, Awadh N et al. Beta2-adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am. J. Respir. Crit. Care Med. 1998 158 : 787 91.
19. Ulbrecht M, Hergeth MT, Wjst M, Heinrich J, Bickeboller H et al. Association of beta 2-adrenoreceptor variants with bronchial hyperresponsiveness. Am. J. Respir. Crit. Care Med. 2000 161 : 469 74.
20. Wechsler ME, Lehman E, Lazarus SC, Lemanske RF Jr, Boushey HA et al. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am. J. Respir. Crit. Care Med. 2006 173 : 519 26.
21. McGraw DW, Almoosa KF, Paul RJ, Kobilka BK, Liggett SB. Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J. Clin. Invest. 2003 112 : 619 26.
22. Sampsonas F, Karkoulias K, Kaparianos A, Spiropoulos K. Genetics of chronic obstructive pulmonary disease, beyond alpha1-antitrypsin deficiency. Curr. Med. Chem. 2006 13 : 2857 73.
23. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K et al. Increased expression of transforming growth factor-beta 1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 2001 163 : 1476 83.
24. Hegab AE, Sakamoto T, Saitoh W, Nomura A, Ishii Y et al. Polymorphisms of TNF-alpha, IL1-beta, and IL1RN genes in chronic obstructive pulmonary disease. Biochem. Biophys. Res. Commun. 2005 329 : 1246 52.
25. Hegab AE, Sakamoto T, Saitoh W, Massoud HH, Massoud HM et al. Polymorphisms of IL4, IL13, and ADRB2 genes in COPD. Chest 2004 126 : 1832 9.
26. Matheson MC, Ellis JA, Raven J, Johns DP, Walters EH et al. Beta2-adrenergic receptor polymorphisms are associated with asthma and COPD in adults. J. Hum. Genet. 2006 51 : 943 51.
27. Ho LI, Harn HJ, Chen CJ, Tsai NM. Polymorphism of the beta 2-adrenoceptor in COPD in Chinese subjects. Chest 2001 120 : 1493 9.
28. Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR et al. Susceptibility genes for rapid decline of lung function in the lung health study. Am. J. Respir. Crit. Care Med. 2001 163 : 469 73.
29. Van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Schouten JP et al. A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am. J. Respir. Crit. Care Med. 2005 172 : 329 33.
30. He JQ, Ruan J, Connett JE, Anthonisen NR, Pare PD et al. Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers. Am. J. Respir. Crit. Care Med. 2002 166 : 323 8.